Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | FBP1 | P09467 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10268494 | 0.95 | TSPO (0.56) | TSPOCYP1A2CYP2C19OPRM1DNM1 | |
| SCHEMBL19559315 | 0.91 | TSPO (0.62) | TSPOCYP1A2CYP2C19OPRM1DNM1 | |
| SCHEMBL410544 | 0.85 | TSPO (0.78) | TSPOCYP1A2CYP2C19OPRM1DNM1 | |
| SCHEMBL19547481 | 0.80 | TSPO (0.58) | TSPOCYP1A2CYP2C19OPRM1DNM1 | |
| SCHEMBL18721926 | 0.79 | TSPO (0.57) | TSPOCYP1A2CYP2C19OPRM1DNM1 | |
| SCHEMBL409824 | 0.78 | TSPO (0.56) | TSPOCYP1A2CYP2C19OPRM1DNM1 | |
| SCHEMBL410648 | 0.78 | TSPO (0.56) | TSPOCYP1A2CYP2C19OPRM1DNM1 | |
| SCHEMBL410170 | 0.77 | DNM1 (0.72) | TSPOCYP1A2CYP2C19OPRM1DNM1 | |
| SCHEMBL410188 | 0.76 | TSPO (1.00) | TSPOCYP1A2CYP2C19OPRM1DNM1 | |
| SCHEMBL409626 | 0.76 | TSPO (1.00) | TSPOCYP1A2CYP2C19OPRM1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183011-B2 | Anti-depression compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-01-22 | — | — | US | claimed |
| US-20180318255-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2018-11-08 | — | — | US | claimed |
| US-9962368-B2 | Pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-05-08 | — | — | US | claimed |
| EP-2590647-B1 | PRO-NEUROGENIC COMPOUNDS | UNIV TEXAS (US) | 2017-11-08 | — | — | EP | claimed |
| US-20170157092-A1 | Anti-depression Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2017-06-08 | — | — | US | claimed |
| US-9616048-B2 | Anti-depression compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-04-11 | — | — | US | claimed |
| US-20160362372-A1 | PRO-NEUROGENIC COMPOUNDS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2016-12-15 | — | — | US | claimed |
| US-9446042-B2 | Pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-09-20 | — | — | US | claimed |
| US-20160206596-A1 | Anti-depression Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2016-07-21 | — | — | US | claimed |
| US-9162980-B2 | Anti-depression compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-10-20 | — | — | US | claimed |
| US-20130190339-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-07-25 | — | — | US | claimed |
| US-20130184301-A1 | Methods of Treating Post-Traumatic Stress Disorder Using Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-07-18 | — | — | US | claimed |
| US-20130184300-A1 | Methods of Treating Traumatic Brain Injury Using Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-07-18 | — | — | US | claimed |
| US-20130184271-A1 | Methods for Treating Parkinson's Disease Using Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-07-18 | — | — | US | claimed |
| EP-2590647-A2 | PRO-NEUROGENIC COMPOUNDS | Board of Regents of the University of Texas System (US) | 2013-05-15 | — | — | EP | claimed |
| US-20130040977-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2013-02-14 | — | — | US | claimed |
| US-8362277-B2 | Pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-01-29 | — | — | US | claimed |
| US-20120022096-A1 | PRO-NEUROGENIC COMPOUNDS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-01-26 | — | — | US | claimed |
| WO-2012006419-A2 | PRO-NEUROGENIC COMPOUNDS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-01-12 | — | — | WO | claimed |
| US-20110003836-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2011-01-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184301-A1 | Methods of Treating Post-Traumatic Stress Disorder Using Pro-Neurogenic Compounds | BDNF, GAP43, DCX | TSPO 478/4885CYP1A2 4729/4885CYP2C19 4839/4885 |
| US-20130184271-A1 | Methods for Treating Parkinson's Disease Using Pro-Neurogenic Compounds | BDNF, GAP43, NES | TSPO 2397/4885CYP1A2 4428/4885CYP2C19 4643/4885 |
| US-20120022096-A1 | PRO-NEUROGENIC COMPOUNDS | BDNF, GAP43, DCX | TSPO 2470/4885CYP1A2 4486/4885CYP2C19 4751/4885 |
| US-20180318255-A1 | Pro-Neurogenic Compounds | BDNF, GAP43, DCX | TSPO 2470/4885CYP1A2 4486/4885CYP2C19 4751/4885 |
| US-20130190339-A1 | Pro-Neurogenic Compounds | DCX, GAP43, BDNF | TSPO 826/4885CYP1A2 4719/4885CYP2C19 4875/4885 |
| US-10183011-B2 | Anti-depression compounds | BDNF, DCX, GAP43 | TSPO 2600/4885CYP1A2 4439/4885CYP2C19 4750/4885 |
| US-20130040977-A1 | Pro-Neurogenic Compounds | BDNF, GAP43, DCX | TSPO 2470/4885CYP1A2 4486/4885CYP2C19 4751/4885 |
| US-20110003836-A1 | Pro-Neurogenic Compounds | DCX, GAP43, BDNF | TSPO 794/4885CYP1A2 4709/4885CYP2C19 4868/4885 |
| US-20130184300-A1 | Methods of Treating Traumatic Brain Injury Using Pro-Neurogenic Compounds | DCX, GAP43, BDNF | TSPO 980/4885CYP1A2 4708/4885CYP2C19 4863/4885 |
| US-20160362372-A1 | PRO-NEUROGENIC COMPOUNDS | DCX, GAP43, BDNF | TSPO 826/4885CYP1A2 4719/4885CYP2C19 4875/4885 |
| US-20160206596-A1 | Anti-depression Compounds | BDNF, DCX, GAP43 | TSPO 2600/4885CYP1A2 4439/4885CYP2C19 4750/4885 |
| US-20170157092-A1 | Anti-depression Compounds | BDNF, DCX, GAP43 | TSPO 2600/4885CYP1A2 4439/4885CYP2C19 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.